We are live on !
Find out more
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter Est. Return
+32.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,270.13%
10 Year Est. Return
+54,096.87%
AUM
$6.66B
AUM Growth
+$1.54B
(+30%)
Cap. Flow
+$235M
Cap. Flow % of AUM
Cap. Flow %
3.53%
Top 10 Holdings %
Top 10 Hldgs %
47.3%
Holding
121
New
27
Increased
30
Reduced
28
Closed
12
Avg Time Held
Equity + Options
1.3
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KARD
Kardigan Inc
KARD
|
+$190M |
| 2 |
Avalyn Pharma
AVLN
|
+$77.2M |
| 3 |
Tango Therapeutics
TNGX
|
+$63.5M |
| 4 |
Relay Therapeutics
RLAY
|
+$63.2M |
| 5 |
Biogen
BIIB
|
+$52.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$209M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$85.9M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
+$37.6M |
| 4 |
Dyne Therapeutics
DYN
|
+$36.8M |
| 5 |
Abivax
ABVX
|
+$28.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.3% |
| 2 | Miscellaneous | 3.58% |
| 3 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Seaport Therapeutics
SPTX
$1.12B
| $10.9M | 0.16% |
+500,000
| New | +$8.8M |
2026 Q2
0 quarters
|
|
77
Viridian Therapeutics
VRDN
$2.64B
| $10.7M | 0.16% |
581,980
-588,849
| -50% | -$9.49M |
2021 Q2
20 quarters
|
|
78
Boston Scientific
BSX
$66.1B
| $10.7M | 0.16% |
+250,000
| New | +$13.6M |
2026 Q2
0 quarters
|
|
79
BillionToOne Inc
BLLN
$5.26B
| $10.4M | 0.16% |
86,812
-5,000
| -5% | -$457K |
2025 Q4
2 quarters
|
|
|
80
Abivax
ABVX
$7.55B
| $9.9M | 0.15% |
74,000
-254,884
| -77% | -$28.8M |
2025 Q3
3 quarters
|
|
81
Natera
NTRA
$58.4B
| $9.42M | 0.14% |
+34,689
| New | +$7.4M |
2026 Q2
0 quarters
|
|
82
enGene Therapeutics
ENGN
$106M
| $8.34M | 0.13% |
4,822,169
-1,005,337
| -17% | -$4.1M |
2025 Q3
3 quarters
|
|
83
Research Alliance Corp III
RACC
$91.7M
| $8.02M | 0.12% |
+750,000
| New | +$7.82M |
2026 Q2
0 quarters
|
|
84
AgomAb Therapeutics NV
AGMB
$422M
| $7.79M | 0.12% |
600,000
| – | – |
2026 Q1
1 quarter
|
|
85
Cullinan Oncology
CGEM
$936M
| $7.77M | 0.12% |
+426,478
| New | +$6.33M |
2026 Q2
0 quarters
|
|
86
uniQure
QURE
$1.5B
| $7.74M | 0.12% |
+168,000
| New | +$4.4M |
2026 Q2
0 quarters
|
|
87
Mobia Medical
MOBI
$357M
| $7.02M | 0.11% |
+523,654
| New | +$6.78M |
2026 Q2
0 quarters
|
|
88
Adagio Medical Holdings
ADGM
$2.65M
| $6.44M | 0.1% |
9,876,586
+10
| +0% | +$10 |
2024 Q3
7 quarters
|
|
89
Guardant Health
GH
$23.2B
| $6.2M | 0.09% |
41,327
-258,673
| -86% | -$28.1M |
2025 Q4
2 quarters
|
|
90
Phathom Pharmaceuticals
PHAT
$481M
| $5.77M | 0.09% |
532,000
-393,000
| -42% | -$4.48M |
2026 Q1
1 quarter
|
|
91
Outlook Therapeutics
OTLK
$125M
| $4.99M | 0.07% |
+3,139,216
| New | +$1.95M |
2026 Q2
0 quarters
|
|
92
Cogent Biosciences
COGT
$5.36B
| $4.69M | 0.07% |
121,082
| – | – |
2025 Q4
2 quarters
|
|
93
Edesa Biotech
EDSA
$25M
| $4.58M | 0.07% |
563,239
| – | – |
2026 Q1
1 quarter
|
|
94
Avalo Therapeutics
AVTX
$363M
| $4.06M | 0.06% |
219,813
+80,146
| +57% | +$1.27M |
2025 Q1
5 quarters
|
|
95
Twist Bioscience
TWST
$9.6B
| $3.79M | 0.06% |
36,812
-113,188
| -75% | -$7.37M |
2026 Q1
1 quarter
|
|
96
Crescent Biopharma
CBIO
$474M
| $3.72M | 0.06% |
206,942
| – | – |
2025 Q2
4 quarters
|
|
97
Xeris Biopharma Holdings
XERS
$1.86B
| $3.7M | 0.06% |
+467,013
| New | +$2.98M |
2026 Q2
0 quarters
|
|
98
Outset Medical
OM
$76.7M
| $3.6M | 0.05% |
833,333
| – | – |
2025 Q1
5 quarters
|
|
99
Biodesix
BDSX
$224M
| $2.45M | 0.04% |
+108,694
| New | +$1.61M |
2026 Q2
0 quarters
|
|
100
Revolution Medicines Inc Warrant
RVMDW
$97.7M
| $2.34M | 0.04% |
250,000
| – | – |
2023 Q4
10 quarters
|
|
Similar funds
Perceptive Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Perceptive Advisors held 121 positions worth $6.66B, up 30% from $5.12B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $235M of net new capital in Q2 2026, opening 27 new positions and adding to 30 existing holdings. Its largest new stake was Kardigan Inc: 8,200,662 shares worth $196M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $85.9M trimmed.
- Perceptive Advisors's largest Q2 2026 buy was Kardigan Inc: 8,200,662 shares worth $196M.
- Perceptive Advisors added most to Tango Therapeutics in Q2 2026, an estimated $63.5M increase.
- Perceptive Advisors's biggest Q2 2026 reduction was Ascendis Pharma A/S, cutting an estimated $85.9M.
- Perceptive Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $209M.
- Perceptive Advisors's ten largest holdings make up 47% of its $6.66B portfolio in Q2 2026.
- Perceptive Advisors opened 27 new positions and closed 12 in Q2 2026.
- Perceptive Advisors's portfolio value rose 30% quarter-over-quarter to $6.66B.
Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.